MMB
2 abstracts
Abstract
Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.Org: Princess Margaret Cancer Centre, University Health Network, Cleveland Clinic Taussig Cancer Institute, University of Florence, AOUC, Clinical Investigation Center,
Abstract
Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy, Wake Forest University School of Medicine, Winston-Salem, NC, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, Analysis Group, Boston, MA, GlaxoSmithKline USA, Collegeville, PA, GlaxoSmithKline, Philadelphia, PA, GlaxoSmithKline Pharmaceuticals, Collegeville, PA, GlaxoSmithKline, Reading, United Kingdom, Analysis Group, Inc, Boston, MA,